Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and b-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P ¼ 0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P ¼ 0.0009). The lipid profile showed a 34% increase in triglyceride levels (Po0.0001), but also a 7% increase in HDL-cholesterol levels (P ¼ 0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDLcholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).
Introduction
Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. OC use increases the risk of venous thromboembolic events by four-fold. 1 In addition, the risk of hypertension, stroke and myocardial infarction may also be slightly increased in women using OC. [2] [3] [4] Since 1995, a fierce debate has been going on about the relative risk of 'third-generation' OC compared to second-generation OC on CV disease. Second-generation OC contain levonorgestrel as a progestagen, while third-generation OC contain desogestrel or gestodene. Third-generation OC also contain lower doses of ethinyloestradiol. A recent meta-analysis concluded that the risk of venous thromboembolic events mildly increased in users of third-generation OC, compared with that in levonorgestrel-containing OC users. 5 However, the risk of stroke was not found to be different among users of second-and third-generation OC. 3 Moreover, the risk of myocardial infarction was recently reported to be lower in third-generation vs second-generation OC users. 4 In Belgium, the majority of OC users is taking thirdgeneration OC. In this study, we explored differences in CV disease markers between 27 mono-zygotic (MZ) twin pairs, in which one twin was taking third-generation OC, whereas the other was not using OC. Studying MZ twins allows perfect paired matching for genetic factors, age and prenatal environment, and very good matching for environmental and lifestyle factors.
Materials and methods

Subjects
Subjects were recruited from the East Flanders Prospective Twin Survey, a register that was started in 1964 and collects data on all twins born in the Belgian province of East Flanders. 6 Monozygosity is ascertained, in sequential order, by gender, chorionicity of the placental membranes on histologic examination, umbilical cord blood group typing, placental alkaline phosphatase, and DNA fingerprints. We randomly contacted from the database 343 female twin pairs to participate in the Prenatal Programming Twin Study; 128 MZ twin pairs agreed to participate. 7 All subjects answered a questionnaire that included questions on the use of OC. Of the 41 twin pairs that were discordant for the use of OC, we selected 27 pairs in which one twin was taking OC containing desogestrel or gestodene, whereas the other twin was not taking OC. The mean duration of OC use was 75 months (median: 60 months; range: 2-240 months). We excluded 14 discordant pairs of whom the OC-user was taking second-generation OC (n ¼ 8), OC containing other progestagens such as cyproterone acetate or norgestimate (n ¼ 2), or when no specific OC brand was mentioned (n ¼ 4). Norgestimate-containing OC are variably classified as second-or third-generation OC, and therefore were not included in the analysis. Progestagen-only pills or first-generation OC were not used by any of the twins. Of the 27 non-OC-users, seven women had never used OC before. The mean duration of previous OC use of the remaining non-OC-users was 61 months (median 57 months, range: 12-144 months).
Mean age was 26.3 years (median: 25.5, range: 22-33 years). All twin pairs were raised within the same family, although most women were now living separately for a mean duration of 3.4 years (median: 2.5, range: 0-15 years). The twins were matched for smoking status, alcohol consumption and physical activity level. In all, 85% (n ¼ 23) were concordant for smoking status (McNemar test for paired data: w 2 ¼ 1.00, 1 df, P ¼ 0.32) and 74% (n ¼ 20) were concordant for regular alcohol consumption (McNemar test for paired data: w 2 ¼ 0.14, 1 df, P ¼ 0.70). The intrapair differences for weekly amount of beer, wine, and liquor consumption were never significant (all P40.5). OC-users performed 0.6 times a week activities that made them sweat, non-OC-users did 0.4/week (P for intrapair difference ¼ 0.43). Also, when the subjects scored their daily activity level on a scale from 0 to 10 (low to high), no differences between OC-users and non-OC-users were observed (resp mean 7 s.d.: 5.0 7 1.7 and 4.7 7 1.9, P for intrapair difference ¼ 0.32). Birth weight of OC users (2.4 7 0.5 kg) and nonusers (2.5 7 0.4 kg) was not significantly different (P for intrapair difference ¼ 0.14). None of the 54 women used medications known to affect blood pressure, or carbohydrate and lipid metabolism.
Measurements and data analysis
Conventional blood pressure (BP) was measured at the right arm in triplicate by sphygmomanometry and auscultation (Korotkoff phases I and V), after 5 min of supine rest. The reported resting BP is the average of the three measurements. Ambulatory heart rate and BP were monitored over 24 h (SpaceLabs 90207, Inc., Redmond, Washington, USA), starting between 06:00 and 09:00 h; measurements were recorded every 15 min between 08:00 and 22:00 h, and every 30 min at night. We obtained 24-h averages, as well as the results for daytime (10:00 to 20:00 h) and night time (midnight to 06:00 h).
Biometric and laboratory measurements were obtained at our research centre during a 2 h morning session. Biometric parameters were recorded as described previously. 7 A blood sample was taken after an overnight fast. Glucose and lipids (HDLcholesterol, total cholesterol, and triglycerides) were measured on an Olympus AU600 Auto-Analyzer (Kyoto, Japan). LDL-cholesterol was estimated using Friedewald's formula. Glucose was measured by the hexokinase method. Insulin was determined by enzyme immunoassay (Abbott, TX, USA); the detection limit is 0.1 mU/l, and within-and between-assay-coefficient of variation (CV) is 3.5 and 5.0%, respectively. Intact proinsulin was measured by enzyme immunoassay (detection limit: p0.5 pmol/l; within-and between-assay CV: 3.0 and 4.3%, respectively) (Mercodia, Uppsala, Sweden). Insulin-like growth factor binding protein-1 (IGFBP-1) was measured by radioimmunoassay, as described previously (detection limit: 25 pg; within-and between-assay CV: 2.4-4.0 and 6.2-9.7%, respectively). 8 Insulin resistance and b-cell function were calculated from fasting glucose and insulin concentrations by the homeostasis assessment model (HOMA). 9 Free cortisol was measured in a 24-h urine collection by competitive immunoassay using direct chemiluminescent technology (Advia s Centaurt, Dublin, Ireland); the detection limit is 0.2 mg/dl, and within-and between-assay CV is 3.0 and 7.0%, respectively.
Statistical analysis was performed using SAS version 6.12 (SAS Institute Inc., Carry, NC, USA). Paired t-tests were used to analyse intrapair differences. All tests were two sided and differences were considered significant at Po0.05. Table 1 shows that there was no difference in the biometric parameters between the twins. However, conventional systolic BP as well as 24-h average heart rate, and systolic and diastolic BP were significantly higher in the twin member who used OC. The differences were comparable for daytime (+4.0 and +3.3 mmHg for systolic and diastolic BP, respectively) and night time (+5.5 and +2.9 mmHg, respectively) values (Po0.01 for all comparisons, except P ¼ 0.06 for night time diastolic BP).
Results
Regarding the glucose-insulin homeostasis, there was no difference in plasma glucose, insulin, or proinsulin concentrations, and in the HOMAderived insulin resistance and b-cell function indices. However, IGFBP-1 levels were markedly higher in OC-users than in nonusers. The lipid profile showed that triglycerides were increased in OC-users compared to nonusers. Both HDL-cholesterol and total cholesterol were higher in OC-users than in nonusers, but there was no difference in LDL-cholesterol or the LDL/HDL-cholesterol ratio. Urinary excretion of free cortisol was not different in users vs nonusers.
Discussion
In this study, we measured markers for CV disease in a small, but well-matched cohort of young adult MZ twins, one of whom was taking third-generation OC. The markers included BP, various laboratory indices of glucose-insulin homeostasis, the lipid profile and the measurement of cortisoluria. Several of these markers have a well-established relation with CV disease, including BP, plasma glucose and insulin levels, and HDL-and LDL-cholesterolaemia. Hypertriglyceridaemia is also a marker of CV disease, although it is uncertain whether it carries the same predictive power as a low HDL-cholesterol or high LDL-cholesterol level. 10 However, other measurements have also been shown to predict CV disease. Proinsulin was found to predict ischaemic heart disease independent of, and more powerfully than, insulin.
11 IGFBP-1, one of the six binding proteins that bind the IGF ligands in the circulation, is expressed in the liver; its secretion is downregulated by insulin. IGFBP-1 is therefore used as a marker of (hepatic) insulin resistance and hyperinsulinaemia. Fasting IGFBP-1 levels correlate negatively with other CV disease markers, such as blood pressure and triglyceride levels. 12 We found that ambulatory systolic and diastolic BP were higher in twin members using thirdgeneration OC, during both daytime and night time. Our data contradict the general assumption that the OC-induced increase in BP is lower or nonexistent in women using low-dose preparations. It was previously reported, in a cross-sectional study in 1930 women, that gestodene-containing OC did not affect BP in 90% of women, but raised BP in about 6% of them. 13 Previous studies used conventional BP measurements. In the current study, the results obtained with 24-h ambulatory BP recording were confirmed by conventional systolic BP but not diastolic BP. This discrepancy may be explained Table 1 Nonuser references (mean (s.e.m.)) and intrapair differences (user-nonuser) in MZ women (n=27 twin pairs) discordant for the use of oral contraception containing gestodene or desogestrel by the greater precision of ambulatory BP monitoring, in view of the large number of measurements. Users of third-generation OC had a different lipid profile, with a robust increase in triglyceride levels (+34%) and a milder increase in total cholesterol (+6.6%) and HDL-cholesterol (+7.0%) levels. These differences are in line with previous data. In an overview on third-generation OC, Speroff and DeCherney 14 calculated that, compared with baseline values, desogestrel-and gestodene-containing OC increased triglyceride levels by 29 and 38%, total cholesterol by 2.8 and 3.8%, and HDLcholesterol by 12.9 and 8.1%, respectively.
The incidence of CV events is very low in youngadult women. While the slight elevation in BP may not have an immediate impact, long-standing BP elevation is expected to induce target organ damage and worsen CV prognosis. On the other hand, the mild increase in the HDL-cholesterol level may confer benefit and oppose the potentially adverse effect of the raised BP on the atheromatotic process.
Third-generation OC did not affect indices of insulin resistance and b-cell function, but there was a marked increase in IGFBP-1 levels (+142%). In a validation study for our IGFBP-1 assay, we measured IGFBP-1 in 71 adult women not on OC and 58 women on OC (any type), and we found that IGFBP-1 levels were increased by 59%. 8 Others have reported similar findings. 15 The rise in IGFBP-1 levels is not explained by changes in insulin concentrations, but is believed to be estrogen entrained, whereas progestagens abrogate the estrogen-induced changes. 15 The ultimate effect of increased IGFBP-1 levels on CV risk is uncertain at this time. Although IGFBP-1 levels correlate with indices of insulin resistance, including BP and lipid levels, 12, 16 a rise in IGFBP-1 levels results in increased formation of binary complexes of IGF-I and IGFBP-1, thereby lowering free (unbound) IGF-I levels. 17, 18 However, lower free IGF-I levels have been related to accelerated atherogenesis and coronary artery disease in elderly individuals. 16 Further research is needed on this issue.
In conclusion, we found that the use of thirdgeneration OC has an impact on several markers of CV disease in young-adult MZ twin members. A mild, but significant, increase in HDL-cholesterol levels is a beneficial effect. Potentially deleterious effects include an unequivocal rise in BP and a robust increase in triglyceride levels. The impact of markedly raised IGFBP-1 levels on CV risk remains to be determined.
